Search
Search
Close this search box.

UK-based Dushey Med Ltd strikes exclusive deal with US hemp firm

UK-based CBD wholesaler Dushey Med Ltd has struck an exclusive trans-Atlantic deal.

The Nottinghamshire firm will import products from EcoGen Biosciences, a major manufacturer in the US, into Britain.

EcoGen Biosciences is described as a ‘leading vertically-integrated manufacturer and supplier of hemp-derived specialty ingredients, proprietary formulations, and private-label finished products in the United States’.

Dushey Med Ltd – which is a member of the European Industrial Hemp Association – will now have exclusive rights to import its products to the UK.

Robert Sidebottom, director at Dushey Med Ltd, said: “We are thrilled to formalise our partnership with EcoGen, the company has continued to demonstrate a commitment to success through the leadership of Garrett Bain, with whom we have been working with for over a year.

“The exclusive deal to supply bulk EcoGen CBD and CBG products directly into the thriving UK market is very exciting.

“As a result of our partnership, we now have access to one of the largest inventories of high-quality CBD and CBG products in the UK – if not Europe.”

Garrett Bain, president of EcoGen Biosciences, said: “Working with Robert and the team at Dushey Med Ltd has been great as their standards and efficacy mirror that of EcoGen.

“We are particularly happy to formalise this partnership that will position both companies as prime sellers of quality products in the cannabis space.”

[activecampaign form=31]

🔒 Risk Management Report • Produced in partnership with RELM
Prohibition Partners RELM
📊 New Report Available Now

Relm Risk Briefing: Cannabis 2026

The global cannabis sector has moved from experiment to enterprise. This comprehensive risk briefing examines how regulation, insurance, and operational practices intersect across the international supply chain, drawing on insights from RELM—the only insurer entirely dedicated to the cannabis industry.

What's covered

  • 🌱 Cultivation risk management — biological contamination, environmental instability, and security protocols
  • ⚗️ Manufacturing & extraction — GMP standards, in-house testing, and quality control measures
  • 🔬 Testing & compliance — rigorous protocols ensuring product safety and regulatory adherence
  • 📦 Distribution & logistics — GDP-aligned transport, route monitoring, and cargo insurance
Key focus areas
Cultivation Manufacturing Testing & QC Packaging Distribution Retail & Pharmacy
100% free • Comprehensive risk analysis

Key insights

Industry Maturity Cannabis has evolved from patchwork markets to international enterprise, with risk management now the measure of long-term stability.
Cultivation Challenges Operators addressing biological contamination through controlled-environment agriculture, tissue culture, and IPM protocols.
Quality Control GMP adherence, in-house testing, and selective supplier relationships emerging as critical control points.
Supply Chain Security GDP-aligned transport, route monitoring, and comprehensive insurance remain essential safeguards.
Market Access Initiatives stabilizing domestic supply and expanding pharmacy training improving patient and consumer access.
Produced by Prohibition Partners in collaboration with RELM—the only insurer dedicated to emerging industries like cannabis.
Partnership
Produced by Prohibition Partners in collaboration with RELM

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?